![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
June 30, 2023
Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023
The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
June 21, 2022
The Group is recognizing Dr. Eads as an exceptional medical oncologist and committed educator who is making significant research contributions as an international disease expert in neuroendocrine tumors and gastroesophageal malignancies
June 21, 2022
ECOG-ACRIN researchers presented a wide range of study results at the 2022 ASCO Annual Meeting
April 15, 2022
The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.